Introduction
Clinical trials show that people with HIV who achieve and maintain viral suppression do not transmit the virus to their sex partners,1,2 a strategy known as “treatment as prevention” (TasP) and promoted under the slogan “Undetectable equals untransmittable” (U=U). Promoting TasP can reduce HIV-related stigma, remove barriers to HIV testing, and encourage engagement in HIV care and treatment adherence.3,4
TasP promotion is particularly important in populations with high HIV prevalence and incidence, including gay, bisexual, and other men who have sex with men (MSM) and transgender, gender nonconforming, and nonbinary (TGNCNB) individuals. In 2022, more than 800,000 men in the United States were living with HIV, and about two thirds of new diagnoses were attributed to male-to-male sexual contact; TGNCNB individuals were also disproportionately affected by HIV.5
Since the launch of the U=U campaign in 2016, surveys that included U.S. sexual- or gender-minority people have found that most respondents were aware of TasP but fewer agreed it would effectively prevent HIV transmission, and even fewer were willing to rely on it.4,6–8 In a 2017–2018 survey with 3268 HIV-negative MSM and TGNCNB individuals, 85% were aware of TasP, but only 42% of those trusted its effectiveness, and far fewer reported willingness to have condomless sex with a partner with suppressed HIV.8
Although some studies have examined individual components of TasP acceptability, few assessed the full continuum of adoption. Drawing from the Precaution Adoption Process Model9 the stages of TasP adoption can be conceptualized as a cascade: gaining awareness of TasP, agreeing with its effectiveness, being willing to rely on it, and using it. The cascade framework has been used in HIV research to look at adoption of PrEP or HIV treatment.10,11 The goal of this study was to map the TasP adoption cascade in a survey of 1443 U.S.
MSM and TGNCNB individuals who have sex with men. Identifying which stages represent the main breakpoints in the cascade can inform the focus of future TasP promotion efforts.
Methods
Participants
We conducted a cross-sectional online survey between December 2020 and June 2021. Participants could self-enroll through advertisements on social media (Facebook, Instagram, and Reddit) or dating/hookup applications (Grindr, GROWLr, and Scruff). Ads indicated that researchers at Columbia University were conducting a study on the sexual health of men and TGNCNB individuals who have sex with men, and that eligible participants who completed the survey would be able to enter a raffle for a $200 gift card.
The ads directed interested participants to the survey page on Qualtrics where, after informed consent, they were asked a few questions to determine eligibility. To proceed to the full survey, respondents had to report: a) being at least 18 years old; b) living in the United States; c) fluency in English; d) identifying as a cisgender man or as transgender, gender nonconforming, or nonbinary; and e) having had sex with a male partner in the previous 12 months. The online survey was initiated 1996 times and 1443 unique participants were eligible and completed the survey.
Measures
The survey elicited demographics and information about sexual health and behaviors (detailed in Table 1). We assessed TasP acceptability using a series of questions (included as supplemental material) we developed based on our review of the relevant literature and prior work on TasP.12,13 For the current report, we looked at four stages of TasP adoption measured as follows:
Analysis
We used descriptive statistics to characterize participants and categorize them along the stages of the TasP adoption cascade. We identified the main breakpoint across the first three stages by examining retention percentages.14 We compared participants across the two stages around the main breakpoint using bivariate binary logistic regressions to assess associations between demographic, behavior, and health variables (α = .1). Variables significant at this level were then included in a multivariable binary logistic regression (α = .05).
Analyses were conducted using SPSS version 28.
Results
Participants’ characteristics are displayed in Table 1. The mean age was 42.9 years old. Participants represented various U.S. regions, though most (60.3%; n = 870) said they resided in large cities and only 3.2% in rural areas.
Most (64.3%; n = 928) identified as White and not Latino, gay or queer (88.1%; n = 1271), and cisgender men (94.4%; n = 1362). About two thirds (66.1%; n = 954) had earned a bachelor’s degree and 65.3% were single. About one fifth of participants (19.2%; n = 277) reported having been diagnosed with HIV and, of them, 92.1% (n = 255) said they had reached viral suppression at their last viral load test.
Among participants who reported having never been diagnosed with HIV, 56.3% (n = 656) had ever used PrEP and 44.8% (n = 522) were currently using it.
Figure 1 illustrates the cascade of TasP adoption across four stages. Awareness (Stage 1) was high, with 82.4% (1189/1443) reporting prior knowledge of TasP. However, nearly half did not progress to Stage 2, as only 52.6% (625/1189) of those aware perceived TasP as effective.
Attrition was minimal to Stage 3, as 83.8% (524/625) of those who perceived effectiveness were also willing to rely on TasP. At Stage 4, 30.2% (158/524) reported recent reliance on TasP, an expected decline given the six-month reference period, the exclusion of TasP use with condoms, and the fact that only participants with a known serodifferent partner could report its use. Accordingly, the most meaningful breakpoint in the cascade was between awareness (Stage 1) and perceived effectiveness (Stage 2).
Across every stage, declines were most pronounced among participants who reported never having been diagnosed with HIV and never having used PrEP. For example, among those aware of TasP, only 39.5% of this group perceived it as effective, compared with 57.0% of participants who reported no HIV diagnosis but had used PrEP, and 62.7% of those who reported an HIV diagnosis.
We compared participants who were aware of TasP but did not perceive it as effective (n = 564) to those who were both aware and perceived it as effective (n = 625) (Table 2). Increased age was associated with lower agreement with TasP’s effectiveness (aOR = 0.98; 95% CI: 0.97–0.99). Compared to White non-Latino participants, those identifying as Latino of any race (aOR = 0.69; 95% CI: 0.49–0.96) or as multiracial or of other race (aOR = 0.40; 95% CI: 0.24–0.67) were less likely to perceive TasP as effective.
Perceived effectiveness was higher among participants who were in serodifferent relationships (aOR = 1.74; 95% CI: 1.05–2.86) and those who had completed a bachelor’s or higher degree (aOR = 1.46; 95% CI: 1.11–1.92). Compared to participants who reported no HIV diagnosis and never using PrEP, those who had used PrEP (aOR = 1.45; 95% CI: 1.07–1.97) and those who had HIV (aOR = 2.14; 95% CI: 1.41–3.24) were more likely to perceive TasP as effective. Participants reporting two or more condomless sex partners in the prior six months were also more likely to perceive TasP as effective (aOR = 1.68; 95% CI: 1.27–2.22).
Finally, participants who reported learning or receiving information about TasP/U=U from community organizations (aOR = 1.35; 95% CI: 1.01–1.81) or from sex or romantic partners (aOR = 1.37; 95% CI: 1.02–1.84) were more likely to perceive TasP as effective.
Discussion
Our survey mapped the stages of TasP adoption among 1443 U.S. men and TGNCNB individuals who have sex with men. While most participants (82.4%) reported prior awareness of TasP, only about half of them (52.6%) also agreed that it was effective at preventing HIV transmission, marking the main breakpoint in the adoption cascade. These findings suggest that, when these data were collected, awareness-raising efforts had been successful, but understanding of TasP’s effectiveness was lagging.
The high awareness and lower perceived effectiveness we observed align with findings from other surveys among MSM or TGNCNB individuals in the United States.4,7,8 This pattern may reflect how early TasP promotion efforts prioritized broad messaging (such as social marketing campaigns featuring the U=U slogan) over detailed education about the strategy. For instance, an analysis of U.S. health departments’ websites found that many only offered vague, incomplete, or inaccurate information about TasP.15 Another study among men with HIV and healthcare providers in the United States and Australia found that providers were often hesitant to educate patients about TasP, or did so ambiguously or inaccurately.16 While TasP promotion appears to have succeeded in raising awareness, additional efforts may be needed to ensure people fully understand and trust its effectiveness. To inform such efforts, we compared participants across these two stages of TasP adoption.
Compared to participants who reported no HIV diagnosis and never having used PrEP, those who had HIV or had used PrEP were significantly more likely to agree that TasP was effective, a pattern consistent with other surveys.4,6–8 Among HIV-negative individuals, those with PrEP experience may be more engaged with sexual-health services, where they can access more detailed information about TasP. Supporting this interpretation, participants who reported learning about TasP from a community organization were also more likely to perceive it as effective. Barriers to PrEP and TasP adoption may also overlap; for example, medical mistrust is a known barrier to PrEP,17 and skepticism about the ability of medications to prevent HIV may similarly shape perceptions of TasP.
For people with HIV, TasP is a key strategy for preventing transmission to partners, and they may be more likely to seek information about it or receive education from providers. However, even though participants with HIV were the most likely of all three groups we examined to perceive TasP as effective, nearly half of them did not. Prior qualitative research with individuals in serodifferent relationships highlighted worries that, despite viral suppression, some residual risk of transmission might remain.18,19 These studies predated the launch of the U=U campaign, which aimed to reduce HIV stigma and improve uptake of treatment among people with HIV.
Examining the reasons why a substantial proportion of people with HIV today remain unconvinced of TasP’s effectiveness will be important to guide future education efforts.
Participants who reported learning or receiving information about TasP from a sex partner were more likely to agree with its effectiveness, along with those who reported having a relationship partner of a different HIV status. Prior studies had discussed how TasP could facilitate relationships across serostatus18 and bridge the “serodivide” between people with and without HIV.20 While our data cannot determine whether TasP understanding leads to serodifferent partnerships or vice versa, it is likely that such experiences prompt deeper engagement with the strategy. For example, participants in a prior qualitative study described increasingly trusting TasP as they kept using it.12 For individuals without serodifferent partners, TasP may remain an abstract concept they feel no need to understand in depth.
Interventions that foster dialogue across HIV status, whether through peer education, provider support, or community programming, may help increase TasP adoption.
We found that participants who identified as Latino or as multiracial were less likely to perceive TasP as effective than those who identified as White, with no significant differences for Black-identifying participants; a pattern similar to that observed in a prior U.S. survey.8 The absence of statistical significance might be attributable to the difficulty of enrolling sufficiently large numbers of Black MSM and TGNCNB individuals to participate in surveys, and should not be interpreted as evidence of no difference. Studies seem to consistently show that there are racial/ethnic disparities in adoption of biomedical HIV prevention, which should be addressed considering how Black and Latino individuals in the United States are disproportionately affected by HIV.5 The low perceived effectiveness of TasP among MSM and TGNCNB individuals of color may reflect medical mistrust; however, such skepticism should not be viewed as a lack of information, but rather as a response to a broader history of exclusionary clinical practices, discrimination in medical settings, and inequitable access to care.21
Most participants (83.8%) who agreed with TasP’s effectiveness also reported willingness to rely on the strategy, representing the third stage of adoption. In a prior qualitative study,12 some participants expressed being unwilling to use TasP despite perceiving it as effective, citing deep-rooted fears about HIV or the difficulty to know a partner’s viral load. While such barriers warrant attention, our findings suggest that only a minority of those who accept TasP’s effectiveness express hesitance to rely on it.
Actual use of TasP (the final stage of adoption) may be less common because it depends on having partners of different HIV status. Nevertheless, 30.2% of participants who were willing to rely on TasP also reported having engaged, in the prior six months, in condomless sex with a serodifferent partner while the person with HIV had an undetectable viral load, indicating that willingness was not purely speculative. These results suggest that once people understand TasP’s effectiveness, progression through the remaining stages of adoption may be more readily achieved.
Our findings are limited by the use of a convenience sample and may not be generalizable to all U.S. men and TGNCNB individuals who have sex with men. Nonetheless, convenience sampling remains one of the most accessible approaches for studying sexual and gender-minority populations, and results from our relatively large sample are consistent with other surveys on TasP.4,6–8 Because participants self-enrolled via advertisements on social media and dating or hookup apps, our findings might be more representative of individuals who use these platforms and are willing to volunteer for public health research. These recruitment strategies may also lead to underrepresentation of people in lower socioeconomic status, from non-urban areas, and of racial/ethnic identifies other than White and not Latino.
The cross-sectional design precludes causal inference. In the absence of validated measures of TasP acceptability, we developed survey items based on prior research, which may limit measurement precision. Self-reported data are subject to recall error and respondent fatigue and, while social desirability bias is likely minimal in self-administered confidential surveys, some participants may have given responses that they perceived as more acceptable than their true beliefs.
Conclusions
Despite these limitations, our study provides a comprehensive view of all stages of TasP adoption among a large sample of U.S. men and TGNCNB individuals who have sex with men, whereas most prior research has examined only selected aspects. Our findings suggest that the main threshold in the TasP adoption cascade is the point at which people move beyond awareness of the strategy to understanding and accepting its effectiveness. While TasP adoption may increase over time as information becomes more widespread, promotion efforts can help reach groups who lag in the process, such as HIV-negative individuals who have never used PrEP.
Reaching out to individuals who are not already connected to sexual-health care services could be done via online meeting platforms or other community spaces. LGBTQ communities of color should be prioritized, and educational interventions should not presume familiarity with complex scientific concepts and anticipate skepticism. Healthcare providers also play a central role in deepening TasP knowledge among their patients and should receive appropriate training to facilitate this process.
Educating community members and patients should not only involve giving information about TasP, but discussing the strategy and how it can be used effectively. Strengthening confidence in TasP’s effectiveness will help the strategy realize its potential to reduce both HIV transmission and HIV-related stigma.
Supplementary Material